



TITLE: COMPOUNDS AND METHODS FOR PHARMICO-GENE THERAPY OF EPITHELIAL SODIUM CHANNEL ASSOCIATED DISORDERS  
 INVENTOR NAME: John F. Engelhardt et al.  
 SERIAL NO.: 10/815,557

1/22

Fig. 1A







Fig. 1B



3/22


Fig. 1C





5/22

Fig. 1F



6/22





Fig.2

7/22





Fig. 3A



8/22




Fig. 3B

9/22




Fig. 4




Fig. 5A

10/22

NO CHEMICAL



Fig. 5B

LLnL 40  $\mu$ M



Fig. 5C

DOX 5 $\mu$ M




Fig. 5D

LLnL 40 $\mu$ M/DOX 5 $\mu$ M




Fig. 5E




Fig. 5F

11/22




Fig. 6




Fig. 7

12/22




Fig. 8A




Fig. 8B

13/22




Fig. 9A




Fig. 9B

14/22




Fig. 10A




Fig. 10B

15/22




Fig. 10C




Fig. 11A

16/22





Fig. 11B

17/22



18/22




Fig. 12




Fig. 13A

19/22




Fig. 13B





Fig. 13C

20/22

Fig. 14A



21/22

SAMPLE	AVG RLU/mg	STDEV	FOLD CHANGE
VEHICLE	2.95E+03	9.01E+02	
AAV2 FLAG-LUCIFERASE	1.11E+05	3.77E+04	1.00
MG-132 - 20 $\mu$ M	1.43E+06	1.72E+06	12.90
DOXORUBICIN 6 $\mu$ g/ML	2.10E+07	4.57E+06	189.36
DOXORUBICIN 3 $\mu$ g/ML	6.55E+06	1.15E+05	58.99
DOXORUBICIN 0.6 $\mu$ g/ML	2.55E+05	1.30E+05	2.30
DAUNORUBICIN 6 $\mu$ g/ML	3.17E+08	1.41E+08	2855.65
DAUNORUBICIN 3 $\mu$ g/ML	2.40E+07	2.72E+06	216.42
DAUNORUBICIN 0.6 $\mu$ g/ML	4.09E+05	6.41E+04	3.69
ELLENCE 6 $\mu$ g/ML	1.06E+08	4.85E+07	952.50
ELLENCE 3 $\mu$ g/ML	1.33E+07	2.70E+06	120.13
ELLENCE 0.6 $\mu$ g/ML	3.81E+05	1.78E+05	3.43
IDAMYCIN 6 $\mu$ g/ML	3.87E+04	2.00E+04	0.35
IDAMYCIN 3 $\mu$ g/ML	5.99E+08	1.91E+08	5396.31
IDAMYCIN 0.6 $\mu$ g/ML	5.30E+07	1.48E+07	477.76

Fig. 14B

22/22

Fig. 15

